| Q44737488 | A minimally invasive approach for efficient gene delivery to rodent hearts |
| Q39398902 | A transendocardial delivery and intracardiac ultrasound irradiation treatment catheter |
| Q30475161 | A visible, targeted high-efficiency gene delivery and transfection strategy |
| Q35061110 | Active inhibitor-1 maintains protein hyper-phosphorylation in aging hearts and halts remodeling in failing hearts |
| Q37766138 | Advances in gene-based therapy for heart failure |
| Q27023090 | Anatomy of the mitral valve apparatus: role of 2D and 3D echocardiography |
| Q34799559 | Basic mechanisms of mitral regurgitation |
| Q42198000 | CRNK gene transfer improves function and reverses the myosin heavy chain isoenzyme switch during post-myocardial infarction left ventricular remodeling |
| Q34409721 | Cardiac Gene Therapy |
| Q37811189 | Cardiac gene therapy with SERCA2a: From bench to bedside |
| Q33730689 | Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach |
| Q45875674 | Experimental research on therapeutic angiogenesis induced by hepatocyte growth factor directed by ultrasound-targeted microbubble destruction in rats |
| Q37939775 | Gene delivery methods in cardiac gene therapy |
| Q34130135 | Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation |
| Q30454594 | Gene therapy for cardiovascular disease mediated by ultrasound and microbubbles |
| Q38132253 | Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium |
| Q40119187 | Gene-therapy delivery strategies in cardiology |
| Q44786807 | Indirect intracoronary delivery of adenovirus encoding adenylyl cyclase increases left ventricular contractile function in mice |
| Q35360600 | Methods to improve cardiac gene therapy expression |
| Q90346534 | Microbubble Formulations: Synthesis, Stability, Modeling and Biomedical Applications |
| Q36779195 | Multilayered polyelectrolyte assemblies as platforms for the delivery of DNA and other nucleic acid-based therapeutics |
| Q43014093 | Myocardial gene and cell delivery |
| Q80532852 | Phospholamban ablation by RNA interference increases Ca2+ uptake into rat cardiac myocyte sarcoplasmic reticulum |
| Q36497159 | Potential of gene therapy as a treatment for heart failure |
| Q48447157 | Refinement of in vivo surgical procedures for cardiac gene and cell transfer in rats. |
| Q34757960 | Rescuing the failing heart by targeted gene transfer |
| Q78757082 | Retrograde coronary perfusion: a superior route to deliver therapeutics to the heart?* |
| Q40910862 | SERCA2a gene therapy for heart failure: ready for primetime? |
| Q50503729 | Targeted endothelial gene delivery by ultrasonic destruction of magnetic microbubbles carrying lentiviral vectors. |
| Q37878086 | Targeted gene therapy for the treatment of heart failure |
| Q92767148 | Targeting protein and peptide therapeutics to the heart via tannic acid modification |
| Q37550406 | Targeting sarcoplasmic reticulum calcium ATPase by gene therapy |
| Q55055161 | The present and future role of ultrasound targeted microbubble destruction in preclinical studies of cardiac gene therapy. |
| Q35968117 | The role of ultrasound in molecular imaging |
| Q40199219 | Treatment of heart failure by calcium cycling gene therapy |
| Q30502960 | Ultrasonic drug delivery--a general review |
| Q36640312 | Ultrasound-induced cavitation: applications in drug and gene delivery |